Skip to main content

Table 2 Rates of medication coverage for patients with diabetes, for the first quarter of each year, EMR cohort

From: Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study

Drug2010Q12011Q12012Q12013Q12014Q12015Q12016Q1
STATIN62.87%64.71%64.26%64.82%63.97%64.01%65.12%
ACE INHIBITORS43.24%43.02%41.33%39.86%38.72%37.97%37.48%
ARB INHIBITORS21.07%21.43%22.25%22.23%22.62%22.43%22.87%
ACE or ARB63.40%63.93%63.10%61.80%61.20%60.34%60.36%
ANTIPLATELETS*9.39%8.84%8.48%7.83%7.39%6.58%6.49%
PPI21.85%23.25%23.79%24.83%25.36%27.32%27.65%
  1. *patients with a history of myocardial infarct were excluded
  2. ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; PPI: proton pump inhibitor